BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Betamethasone Acetate And Betamethasone Sodium Phosphate, and when can generic versions of Betamethasone Acetate And Betamethasone Sodium Phosphate launch?
Betamethasone Acetate And Betamethasone Sodium Phosphate is a drug marketed by Am Regent and Hikma and is included in two NDAs.
The generic ingredient in BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE is betamethasone acetate; betamethasone sodium phosphate. There are sixty-six drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the betamethasone acetate; betamethasone sodium phosphate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Betamethasone Acetate And Betamethasone Sodium Phosphate
A generic version of BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE was approved as betamethasone acetate; betamethasone sodium phosphate by AM REGENT on July 31st, 2009.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE?
- What are the global sales for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE?
- What is Average Wholesale Price for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE?
Summary for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 2 |
| DailyMed Link: | BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE at DailyMed |
Recent Clinical Trials for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Tel-Aviv Sourasky Medical Center | N/A |
| University of Kentucky | Early Phase 1 |
| Edward Kasaraskis | Early Phase 1 |
See all BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE clinical trials
Pharmacology for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
US Patents and Regulatory Information for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Am Regent | BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE | betamethasone acetate; betamethasone sodium phosphate | INJECTABLE;INJECTION | 090747-001 | Jul 31, 2009 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Hikma | BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE | betamethasone acetate; betamethasone sodium phosphate | INJECTABLE;INJECTION | 077838-001 | Jan 17, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
